SureTrader Advertisement Advertisement Advertisement
Home > Boards > US Listed > Biotechs >

Opko Health Inc (OPK)

Add OPK Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator dshade, stonsetr, now invest
Search This Board:
Last Post: 10/5/2015 8:16:43 AM - Followers: 148 - Board type: Free - Posts Today: 4
Opko Health Initiates Phase 3 Trial of Bevasiranib for the Treatment of AMD Wednesday July 11, 8:00 am ET -Trial Designed to Compare Efficacy of Bevasiranib Administered Every 8 Weeks or 12 Weeks with Lucentis(R) Administered Every 4 Weeks- -Represents First-Ever Phase 3 Pivotal Trial of an RNAi Therapeutic- MIAMI, July 11 /PRNewswire-FirstCall/ -- Opko Health Inc. (Amex: OPK - News) today announced the initiation of the Phase 3 COBALT (Combining Bevasiranib And Lucentis Therapy) clinical trial of bevasiranib for the treatment of wet age-related macular degeneration (wet AMD.) The multi-national COBALT study is currently open and enrolling patients. The trial will include more than 330 wet AMD patients and will assess whether bevasiranib administered every 8 or 12 weeks is safe and has equivalent efficacy in preventing vision loss as Genentech's Lucentis® administered every four weeks. ADVERTISEMENT Bevasiranib is a first-in-class small interfering RNA (siRNA) drug designed to silence the genes that produce vascular endothelial growth factor (VEGF), believed to be largely responsible for the vision loss of wet AMD. Bevasiranib is the first therapy based on the Nobel Prize-winning RNA interference (RNAi) technology to advance to Phase 3 clinical trials. "This first-ever Phase 3 trial of an agent based on RNAi technology is an important milestone in this new field. We are proud of the ability demonstrated by our clinical group to have successfully moved this innovative compound through development rapidly and cost effectively," said Philip Frost, M.D., Chairman and CEO of Opko Health. "Currently patients with wet AMD undergo intravitreal injections every four weeks to achieve the vision- preserving benefits of Lucentis, so the potential ability of bevasiranib to achieve similar results while requiring less frequent injections would be an important benefit for these patients who often have limited mobility." "Bevasiranib's demonstrated safety profile, its ability to inhibit the growth of the retinal lesions associated with wet AMD and its potential for prolonged duration are a promising foundation for this pivotal trial," said Lawrence Singerman M.D., founder and Executive Secretary of the Macula Society, Clinical Professor of Ophthalmology at Case University and a Principal Investigator for the Phase 3 study. "Bevasiranib's potential to serve as a long-term maintenance therapy for wet AMD could provide important benefits to patients, and I look forward to helping to assess its utility in this groundbreaking study." "We are very pleased at the enthusiastic reception the COBALT trial has received from retinal centers around the globe," said Denis O'Shaughnessy, Ph.D., Senior Vice President of Clinical Development at Opko. "Retinal physicians are keenly aware of the burden that frequent drug injections places on elderly patients and their families, and they are eager to help test an innovative new approach that has the potential to significantly reduce that burden while preserving patients' vision." About Wet AMD Wet age-related macular degeneration is the leading cause of irreversible vision loss in the developed world and its incidence is growing rapidly. Advanced age is the main risk factor for wet AMD, and it is expected to become an increasingly common condition as the population grows older. An estimated 1.65 million Americans have wet AMD today and an estimated 11 million people worldwide will have AMD by 2013. Until recently, treatments for wet AMD were of limited efficacy. In the search for more effective treatments, researchers targeted VEGF, shown to be a key cause of the excess growth and leakiness of ocular blood vessels that result in loss of vision in these patients. Current VEGF antagonists, such as Lucentis, slow this vision loss, but require injections into the eye every four weeks, a particular issue for elderly patients who often have limited mobility. Opko Health, Inc. Announces Early Termination of Hart-Scott-Rodino Waiting Period for Proposed Purchase of Shares by Dr. Phillip Frost Thursday July 12, 8:00 am ET MIAMI July 12 /PRNewswire-FirstCall/ -- Opko Health Inc. (Amex: OPK - News) today announced that that the U.S. Department of Justice has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in connection with the potential acquisition of additional shares of Opko Health common stock by Dr. Phillip Frost, CEO and Chairman of Opko. Dr. Frost has requested clearance to purchase additional shares of Opko Health common stock, which this action by the Justice Department now makes feasible.
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
OPK News: Statement of Changes in Beneficial Ownership (4) 09:02 AM
OPK News: Statement of Changes in Beneficial Ownership (4) 10/02/2015 07:20:06 AM
OPK News: Current Report Filing (8-k) 10/01/2015 04:09:56 PM
OPK News: Conversion Right Extended on OPKO 3.0% Convertible Senior Notes 10/01/2015 04:00:00 PM
OPK News: Statement of Changes in Beneficial Ownership (4) 10/01/2015 07:15:30 AM
News News Alert: Statement of Changes in Beneficial Ownership (4) 10/05/2015 09:02:57 AM
#3864  Sticky Note I added a discussion on PSA tests because stargazer123 06/20/15 12:58:21 AM
#3215  Sticky Note Pfizer Partners With Young Little Known Biotech For tomsylver 12/18/14 09:06:21 AM
#4189   Well shorts are worried we might have a now invest 10/05/15 08:16:43 AM
#4188   That's ok.. I will load up if that happens game7alcs 10/05/15 08:06:40 AM
#4187   I think we will see sub 7 first. Quokkie 10/05/15 05:43:37 AM
#4186   Thanks. Quokkie 10/05/15 04:44:49 AM
#4185   I don't necessarily follow Frost. I keep buying game7alcs 10/04/15 12:08:27 PM
#4184   Hard to say 3 years out. I do Picks77 10/04/15 09:56:59 AM
#4183   So you guys trade frost instead of holding Quokkie 10/04/15 09:52:45 AM
#4182   Great !! You wait and hope that now invest 10/02/15 11:05:39 PM
#4181 Washington Regional says new blood tests WiseFool 10/02/15 10:42:29 PM
#4180   So what? It shows the confidence in what game7alcs 10/02/15 09:29:41 PM
#4179   He is a billionaire So what My money is harder Quokkie 10/02/15 07:23:11 PM
#4178   Some fool put in a market order in DegenerateGambler 10/02/15 07:03:50 PM
#4177   Nice day in OPK land!! now invest 10/02/15 04:28:37 PM
#4176   yep dshade 10/02/15 03:47:38 PM
#4175   You all may have missed this last chance DegenerateGambler 10/02/15 03:40:39 PM
#4174   Frost bought another $437K yesterday... now invest 10/02/15 10:13:13 AM
#4173   Explains alot. mgland 10/02/15 09:51:28 AM
#4172   Not good for pps imo Quokkie 10/02/15 09:49:46 AM
#4171   Conversion Right Extended on OPKO 3.0% Convertible Senior Notes mgland 10/02/15 09:46:10 AM
#4170   Not a chance game7alcs 10/01/15 08:29:11 PM
#4169   Why not call and find out... now invest 10/01/15 08:11:45 PM
#4168   CEO = largest single shareholder? pba 10/01/15 07:58:52 PM
#4167   Hey... Just noticed... LOLOL.... WOW... NO WORRIES now invest 10/01/15 07:35:05 PM
#4166   about 22% dshade 10/01/15 04:20:52 PM
#4164   I do not agree, at 60%+ off the Warhead 10/01/15 02:23:11 PM
#4163   Hmmm...shorts seem to be winning....Ah...guess we can't win pba 10/01/15 01:45:57 PM
#4162   Opko Health Europe Events WiseFool 10/01/15 10:02:23 AM
#4161   Another $584K yesterday.. now invest 10/01/15 09:29:04 AM
#4160   Yes, I would be happy with 8.5 too. BigPennyHunter 09/30/15 03:01:39 PM
#4159   Although I am down a little from the DegenerateGambler 09/30/15 11:17:37 AM
#4158   Frost spent another $251K yesterday... now invest 09/30/15 10:14:42 AM
#4157   I'd rather see it at the 3 digit game7alcs 09/30/15 08:30:33 AM
#4156   Just thinking..... What if Frost put together now invest 09/30/15 07:15:01 AM
#4155   I don't see another stock with as much BigPennyHunter 09/30/15 01:40:33 AM
#4154   I just bought more. Whenever I have a game7alcs 09/29/15 09:51:51 AM
#4153   4k and growth hormone from ProLar acquisition are homeruns dshade 09/29/15 09:35:55 AM
#4152   Thanks for the information from the perspective of game7alcs 09/29/15 09:07:47 AM
#4151   I too question any "concerns" over the 4kscore DegenerateGambler 09/29/15 01:21:57 AM
#4150   That is the first I heard anybody questioning game7alcs 09/28/15 11:56:54 AM
#4149   Analyst Michael Petusky: Bio-Reference Acquisition Tranforms OPKO into tomsylver 09/28/15 11:10:55 AM
#4147   No wonder he's a billionaire. We should be game7alcs 09/28/15 10:38:47 AM
#4146   $1.8 million buy on Friday.. now invest 09/28/15 09:39:43 AM
#4145   OPKO Health is Positioned for Strength and Growth WiseFool 09/28/15 09:28:14 AM
#4144   Strong company and great long play. Look for ronk 09/28/15 12:25:17 AM
#4143   I think you are way off track here. game7alcs 09/27/15 08:18:40 PM
#4142   I think the share dumping is back. 11.3 legalizeMJ 09/27/15 06:50:12 PM
#4141   Nice! Adding every chance I get at these levels game7alcs 09/25/15 09:24:32 PM
#4140   Added more today. someconcerns 09/25/15 07:16:22 PM
#4139   It's definitely bargain basement prices for the long game7alcs 09/25/15 04:20:21 PM